Table 1 Patient characteristics at time of starting tenofovir
Royal Free | Pune | ||
|---|---|---|---|
N | 574 (100.0) | 708 (100.0) | |
Age (years) | Median (IQR) | 41 (35, 47) | 38 (34, 45) |
Gender | Male | 439 (76.5) | 537 (75.8) |
Female | 135 (23.5) | 171 (24.2) | |
Ethnicity | White | 339 (59.1) | - |
Black | 161 (28.1) | - | |
Indian | - | 708 (100.0) | |
Other | 74 (12.9) | - | |
Risk for HIV transmission | MSM | 333 (58.0) | - |
Heterosexual | 224 (39.0) | - | |
Other | 17 (3.0) | - | |
CD4 count (cells/mm3) | Median (IQR) | 348 (230, 525) N = 571 | 242 (118, 395) N = 657 |
HIV RNA viral load (log copies/ml) | Median (IQR) | 4.2 (<1.7, 5.0) N = 536 | N/A |
ART-naïve when started TDF | Yes | 314 (54.7) | 307 (43.4) |
No | 260 (45.3) | 401 (56.6) | |
Time since first ART at time of starting TDF (weeks) | Median (IQR) | 368 (217, 545) N = 260 | 162 (66, 274) N = 400 |
Other ARVs in regimen | Emtricitabine | 530 (97.2) | 641 (90.5) |
Lamivudine | 28 (4.9) | 61 (8.6) | |
Zidovudine | 10 (1.7) | 62 (8.8) | |
Didanosine | 1 (0.2) | 1 (0.1) | |
Abacavir | 22 (3.8) | 2 (0.2) | |
Lopinavir | 152 (26.5) | 49 (6.9) | |
Atazanavir | 88 (15.3) | 125 (17.7) | |
Darunavir | 35 (6.1) | 0 (0.0) | |
Saquinavir | 28 (4.9) | 1 (0.1) | |
Fos-amprenavir | 16 (2.8) | 0 (0.0) | |
Nelfinavir | 2 (0.4) | 0 (0.0) | |
Ritonavir | 308 (53.6) | 181 (25.6) | |
Efavirenz | 211 (36.8) | 341 (48.2) | |
Nevirapine | 50 (8.7) | 183 (25.9) | |
Etravirine | 7 (1.2) | 0 (0.0) | |
T20 | 1 (0.2) | 0 (0.0) | |
Raltegravir | 13 (2.3) | 0 (0.0) | |
Maraviroc | 2 (0.4) | 0 (0.0) | |
Stavudine | 13 (1.8) | ||
Indinavir | 6 (0.9) | ||
Baseline eGFR | Median (IQR) | 102 (89, 117) | 100 (82, 119) |
Baseline creatinine | Median (IQR) | 77 (68, 87) | 79 (62, 88) |